GFM
RIGL icon

GF Fund Management’s Rigel Pharmaceuticals RIGL Stock Holding History

GF Fund Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Sell
381
-26
-6% -$802 ﹤0.01% 506
2026
Q1 		$11K Buy
407
+51
+14% +$1.71K ﹤0.01% 552
2025
Q4 		$15.2K Sell
356
-28
-7% -$1.05K ﹤0.01% 537
2025
Q3 		$10.9K Sell
384
-67
-15% -$2K ﹤0.01% 548
2025
Q2 		$8.45K Hold
451
– – ﹤0.01% 584
2025
Q1 		$8.11K Buy
451
+81
+22% +$1.64K ﹤0.01% 585
2024
Q4 		$6.22K Buy
+370
New +$7.1K ﹤0.01% 600

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's RIGL Position: Q2 2026 in Review

GF Fund Management reduced its Rigel Pharmaceuticals (RIGL) stake by 6.4% in Q2 2026, selling an estimated $802 and leaving 381 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #506.

GF Fund Management first reported a position in RIGL in Q4 2024 and has held it in 7 quarters since. The position peaked at $15.2K in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • GF Fund Management held 381 shares of Rigel Pharmaceuticals worth $14.9K as of Q2 2026.
  • GF Fund Management sold 26 Rigel Pharmaceuticals shares in Q2 2026, an estimated $802.
  • Rigel Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #506 holding.
  • GF Fund Management first reported a position in Rigel Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Rigel Pharmaceuticals position peaked at $15.2K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.